Acyclovir

SKU: orb1224546

Description

An antiviral agent that competitively inhibits and inactivates HSV-specified DNA polymerases preventing further viral DNA synthesis without affecting the normal cellular processes; primarily used for the treatment of HSV infections.HSV Infection Approved(In Vitro):Acyclovir (Aciclovir, 3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent.Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner.Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation.(In Vivo):Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 59277-89-3
• MW: 225.2046
• Purity: >98% (HPLC)
• Formula: C₈H₁₁N₅O₃
• SMILES: NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
• Target: HSV
• Solubility: 10 mM in DMSO

Bioactivity

• In Vivo:
  Acyclovir (20 mg/kg; p.o. ; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production. Animal model: Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1. Dosage: 20 mg/kg. Administration: Oral administration; three times daily; for 10 days. Result: Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.
• In Vitro:
  Acyclovir (Aciclovir, 3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent. Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner. Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation. Cell Viability Assay Cell line: Jurkat, U937 and K562 leukemia cells. Concentration: 3, 10, 30 and 100 μM. Incubation time: 24, 48 and 72 hours. Result: Showed a dose- and time-dependent reduction of cell viability. Apoptosis Analysis. Cell line: Jurkat cells. Concentration: 10 and 100 μM. Incubation time: 24, 48 and 72 hours. Result: Increased of caspase-3 activity and cleavaged the internucleosomal DNA. Cell Cycle Analysis Cell line: Jurkat cells. Concentration: 10 and 100 μM. Incubation time: 24, 48 and 72 hours. Result: Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Aciclovir | Acycloguanosine

Quick Database Links

Gene Symbol

HSV